Mr. Mike Withrow reports

ABATTIS ANNOUNCES UP TO $2M PRIVATE PLACEMENT

Abattis Bioceuticals Corp. has proposed a private placement of up to $2-million. Under the terms of the private placement, Abattis will issue up to two million units at a price of $1 per unit. Each unit will consist of one common share and one share purchase warrant. Each warrant will be exercisable into one common share at a price of $1.12 per share for a period of 18 months from the date of issue, subject to acceleration. The warrants will contain an acceleration component whereby Abattis will have the right to shorten the exercise period of the warrants to 30 days if its common shares close on the Canadian Securities Exchange at or above $1.45 per share for a period of 10 consecutive trading days at any time after the statutory four-month-and-one-day hold period expires. Proceeds from this offering will be used for acquisitions, joint venture opportunities, research and development, working capital, general corporate purposes, identifying opportunities to expand the Phytalab brand, and setting up or acquiring labs in states where marijuana is legalized to ensure safety, efficacy and dosing of marijuana products that follow the American Herbal Pharmacopoeia cannabis monograph, which was sponsored, in part, by the company in 2013.

Mike Withrow, president and chief executive officer of Abattis, stated: "We are pleased with the progress Phytalab.com has made in preparation of its soft launch on May 15 in Washington state. Phytalab is a complementary business to its Canadian counterpart, Northern Vine Canada Inc. Upon obtaining a controlled substance licence, Northern Vine will study the chemistry, pharmacology, therapeutic uses, toxicology of cannabis, and its constituents of synthetic and endogenous compounds that interact with cannabinoid receptors and of any compounds that target other components of the endocannabinoid system. A portion of these funds will be used to further Abattis's patent-pending IP described as nutritional supplements that increase nitric oxide tissue levels, with a goal to include the applicable compounds present in cannabis and increase the effectiveness of the company's novel technology. We also own an all-natural proprietary migraine formula that is a candidate for utilizing compounds found in cannabis and will explore this area as well."

We seek Safe Harbor.